Beth Jantzen
August 12th, 2024
Recent Posts
- Applied DNA Sciences to Begin Trading Under New Ticker ‘BNBX’ Reflecting Digital Asset Treasury Strategy
- Applied DNA Sciences Announces Private Placement of Up To $58 Million To Initiate BNB Treasury Strategy and BNB Native Yield Generation
- Applied DNA Abstracts Selected for Poster Presentations Showcasing LineaDNA and LineaIVT Platforms at Upcoming mRNA and CAR T Industry Conferences
- Applied DNA Reports Third Quarter Fiscal 2025 Financial Results
- Applied DNA Announces New Follow-On LineaDNA™ Order from Global IVD Manufacturer for Use in Cancer Diagnostic Application
- Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements
- Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx
- Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
- Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3’25 Financial Results Report in Mid-August
- Applied DNA Reschedules Intra-Quarter Webcast and Investor Update Call to June 17
